The global placental stem cell therapy market was valued at US$ 0.6 Bn in 2020 and is expected to reach US$ 4.5 billion by 2030 with a CAGR of 21% from 2021 to 2030.
Mesenchymal stem cells are emerging as powerful immunomodulators that are playing a key role in advancements made for the treatment of severe COVID-19 patients. MSC-based therapies hold future prospects for companies in the placental stem cell therapy market to create therapeutics for bronchopulmonary dysplasia (BPD) in infants born prematurely. MSCs have proven paracrine activity, which helps migrate toward inflamed sites and improves outcomes in patients suffering from neurological disorders. Ethical issues and immune mediated rejection of transplanted cells are posing as hurdles in the treatment of congenital metabolic diseases. Hence, companies should increase the production of human amniotic epithelial cells (hAECs) that are emerging as an alternative to hepatocyte transplantation (HT) for patients suffering from congenital metabolic diseases.
The placental mesenchymal stem cells therapy is gaining popularity as a potential solution for the treatment of severe COVID-19. The Institute of Cell Therapy is acquiring recognition for successfully curing COVID-19 patients with the help of placental stem cells lacking ACE-2 receptor, which hold promising potentials in the treatment of coronavirus pneumonia. As such, worldwide inoculation of coronavirus vaccines from India has caused a slowdown in research activities of the placental stem cell therapy market. Stakeholders in the placental stem cell therapy market are anticipated to continue their research for minimizing the impacts of future coronavirus-like outbreaks. They are boosting clinical trials to evaluate the efficacy of stem cells of different types for the treatment of COVID-19 in China.
MSC-based Therapies Help in Treatment of Respiratory Diseases Mesenchymal stromal cell (MSC)-based therapies are appearing as new therapeutic strategies for lung diseases. Idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), and acute respiratory distress syndrome (ARDS), among others, have triggered the demand for mesenchymal stromal cell-based therapies. MSCs are being publicized as multipotent cells with immune modulatory and regenerative properties. This explains why the placental stem cell therapy market is estimated to progress at an astonishing CAGR of 20% during the assessment period. The acute respiratory distress syndrome is emerging as an ideal target for the mesenchymal stromal cell-based therapy, since MSCs act as immunomodulatory cells via rapid-acting paracrine effects. Companies in the placental stem cell therapy market are increasing efforts to conduct pre-clinical studies that demonstrate the efficacy of MSCs for ARDS. Hepatocytes Generated from Stem Cells Show Potential in Treatment of Congenital Metabolic Diseases Since congenital metabolic diseases are associated with morbidity due to invasive procedures such as liver transplant, healthcare companies in the placental stem cell therapy market are capitalizing on this opportunity to offer regenerative cell therapies. Regenerative therapy using hepatocytes generated from stem cells has the potential to treat congenital metabolic diseases. This technique is gaining popularity as a less invasive cell replacement approach, suitable for the treatment of congenital metabolic diseases. Embryonic stem cells are prone to risks of tumorigenicity and difficulties with cell expansion, owing to the number needed for the anticipated therapeutic effect. Human amniotic epithelial cells (hAECs) have caught the attention of companies in the placental stem cell therapy market to treat congenital metabolic diseases. Combined Transplantation of Allogeneic Stem Cells Being Used to Cure Neurological Diseases Cell therapy of neurological diseases is gaining momentum in the placental stem cell therapy market. Stem and progenitor cells are showing positive therapeutic results in animal models of neurological disorders within clinical trials. It has been found that each cell being tested has its advantages and drawbacks, owing to unique molecular mechanisms of action. This has led to the concept of combined transplantation of two or more cells. The transplantation of various types of autologous or allogeneic stem/progenitor cells, including embryonic and induced pluripotent stem cells, has shown promising therapeutic outcomes in animal models of neurological diseases. Such findings are translating into revenue opportunities for companies in the placental stem cell therapy market.
In terms of application, the global placental stem cell therapy market has been divided into hematologic malignancies and disorders, congenital immunodeficiency disorders, metabolic disorders, neurological disorders, and others.
The neurological disorders segment held a significant share of the global placental stem cell therapy market in 2020. Based on end user, the global placental stem cell therapy market has been split into hospitals & specialty clinics, clinical research organizations, and research institutes & academies.
The clinical research organizations segment held a significant share of the global placental stem cell therapy market in 2019.
Asia Pacific held a major share of the global placental stem cell therapy market in 2019. Presence of key players and growth strategies adopted by these players are key factors driving the placental stem cell therapy market in the region. North America accounted for the second-largest share of the global placental stem cell therapy market in 2019. The expansion of the market in the region can be attributed to a well-developed healthcare sector. The placental stem cell therapy market in North America is likely to expand at a rapid pace during the forecast period. Technological developments in placental stem cell therapy is another major factor that is likely to propel the placental stem cell therapy market in the region.
Prominent players operating in the global placental stem cell therapy market include Lifebank Stem Cell Banking Celularity, Inc. Americord Registry ReeLabs Pvt. Ltd. Pluristem Therapeutics, Inc. Mesoblast Limited ReNeuron Group plc Athersys, Inc.
Hematologic Malignancies and Disorders
Congenital Immunodeficiency Disorders
By End User
Hospitals & Specialty Clinics
Clinical Research Organizations
Research Institutes & Academies
Middle East & Africa
Scope of the Report
VRR’s report on the global placental stem cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global placental stem cell therapy market for the period 2018–2030, considering 2020 as the base year and 2030 as the forecast year.
The report also provides the compound annual growth rate (CAGR %) of the global placental stem cell therapy market from 2020 to 2030. The report has been prepared after an extensive primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the placental stem cell therapy market. Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the placental stem cell therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global placental stem cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global placental stem cell therapy market. The report delves into the competition landscape of the global placental stem cell therapy market. Key players operating in the global placental stem cell therapy market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global placental stem cell therapy market profiled in this report.
What is the sales/revenue generated by the placental stem cell therapy market across all regions during the forecast period?
What are the opportunities in the global placental stem cell therapy market?
What are major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which drug class segment is expected to generate the highest revenue globally in 2030?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Research Objectives and Research Approach
The comprehensive report on the global placental stem cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of objectives behind this study, and key vendors and distributors operating in the market and regulatory scenario for approval of the products. For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global placental stem cell therapy market in terms of application, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global placental stem cell therapy market.
Retinal Disorders Treatment Market (By Indication: Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, and Others; By Therapeutic Class; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Dystrophic Epidermolysis Bullosa Treatment Market (By Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, Others; By Disease Type: DDEB and RDEB; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Bromelain Market (By Application: Food & Beverages, Healthcare & Pharmaceuticals, Cosmetics, and Other Industries; By Source: Stem and Fruit) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Chronic Idiopathic Constipation Treatment Market (By Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, Others; By Route of Administration: Oral and Rectal; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Hemoglobin Feed Market (By Source: Bovine, Swine, Poultry, Shark, Synthetic, Others; By Application: Industrial and Commercial) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...